Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of OnapriStone in CoMbInation With FuLvestrant for Patients With ER-positive, and HER2-negative Metastatic Breast Cancer After Progression on Endocrine Therapy and CDK 4/6 Inhibitors

NCT04738292 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT04738292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04738292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of OnapriStone in CoMbInation With FuLvestrant for Patients With ER-positive, and HER2-negative Metastatic Breast Cancer After Progression on Endocrine Therapy and CDK 4/6 Inhibitors
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Terminated
Start date
October 5, 2021
Completion date
May 15, 2023
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

er-positive breast cancer, her2-negative breast cancer, metastatic cancer